Fortis Healthcare (FORTIS) investor relations material

Executive summary

• Consolidated revenue rose to INR 2,167 Cr in Q1 FY26, up 16.6% year-over-year, with net profit at INR 254 Cr, and EBITDA at INR 491 Cr, reflecting strong growth across hospital and diagnostics segments.

• Acquired Shri Man Super Speciality Hospital (228 beds) and signed O&M agreement with Gleneagles India for 700 beds, expanding network to 33 facilities and over 5,700 beds in 11 states.

• Achieved clinical milestones, including India's first combined robot-assisted heart bypass and breast cancer surgery.

• Board recommended a dividend of ₹1.00 per equity share for FY25, subject to approval.

• Appointment of BSR & Co. LLP as Tax Auditors for FY24-25 was approved.

Financial highlights

• Consolidated revenue grew 16.6% year-over-year to INR 2,167 Cr; hospital revenue up 18.6% to INR 1,838 Cr; diagnostics gross revenue up 7.4% to INR 369 Cr.

• Consolidated operating EBITDA rose 43.2% to INR 491 Cr, margin at 22.6% vs 18.4% last year.

• Profit after tax before exceptional items increased 46.2% to INR 254 Cr.

• Net debt at INR 1,869 Cr, net debt/EBITDA at 0.92x (up from 0.22x), mainly due to acquisitions.

• Consolidated net profit margin improved to 11.76% from 9.38% year-over-year.

Outlook and guidance

• Hospital and diagnostics businesses expected to maintain positive trajectory, with margin improvement guidance of 200 bps for the year.

• Diagnostic margins guided at 22–23% for FY26, with normalization expected in Q3.

• High single-digit to low double-digit revenue growth expected in diagnostics over the next 6–8 quarters.

• ARPU growth guidance maintained at 6% annually.

• Management expects no material additional impact from ongoing regulatory investigations, with all known financial impacts already provided for.